Danske Banks ordinære generalforsamling 2023
| Selskabsmeddelelse nr. 2 2023 | Danske Bank A/S Holmens Kanal 2-12 1092 København K Telefon 45 14 14 00 16. marts 2023 |
På Danske Banks ordinære generalforsamling torsdag den 16. marts 2023 blev
- årsrapporten for 2022 og forslag til dækning af tab i henhold til den godkendte årsrapport for 2022 godkendt,
- bestyrelsens forslag til aflønningsrapport (Remuneration Report 2022) godkendt ved vejledende afstemning,
- Martin Blessing, Jan Thorsgaard Nielsen, Lars-Erik Brenøe, Jacob Dahl, Raija-Leena Hankonen-Nybom, Allan Polack, Carol Sergeant og Helle Valentin blev genvalgt til bestyrelsen,
- Deloitte Statsautoriseret Revisionspartnerselskab genvalgt som revisor,
- bestyrelsens forslag til vedtægtsændringer om:
- forlængelse med et år af den eksisterende bemyndigelse i vedtægternes § 6, stk. 5.b. og stk. 6 til at forhøje aktiekapitalen uden fortegningsret for aktionærerne og optagelse af konvertible lån godkendt,
- bemyndigelse til at afholde fuldstændig elektronisk generalforsamling godkendt,
- bestyrelsens forslag om forlængelse af bestyrelsens eksisterende bemyndigelse til indtil den 1. marts 2028 at erhverve egne aktier godkendt,
- bestyrelsens forslag til uændrede bestyrelseshonorarer for 2023 godkendt,
- bestyrelsens forslag til justering af aflønningspolitikken (Remuneration Policy 2023) godkendt,
- bestyrelsens forslag vedrørende fornyelse af den eksisterende skadesløsholdelse af bestyrelsesmedlemmer og ledende medarbejdere (Directors and Officers) med virkning indtil den ordinære generalforsamling i 2024 godkendt, og
- bestyrelsens forslag om bemyndigelse til dirigenten godkendt.
Generalforsamlingen vedtog ikke følgende aktionærforslag om
- politikken for direkte udlån i Climate Action Plan og Position Statement on Fossil Fuels,
- asset management politikken i Climate Action Plan, og
- lån til og investeringer i selskaber som har aktiviteter indenfor efterforskning og udvikling af nye forekomster af fossile brændsler.
Umiddelbart efter afholdelsen af den ordinære generalforsamling konstituerede bestyrelsen sig med Martin Blessing som formand for bestyrelsen og Jan Thorsgaard Nielsen som næstformand.
Sammensætningen af bestyrelsesudvalgene vil snarest muligt blive offentliggjort på danskebank.com under ”Vores ledelse”.
Danske Bank
Kontaktperson: Pressechef Stefan Singh Kailay, telefon 45 14 14 00
Vedhæftet fil
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Sodexo announces solid H1 Fiscal 2024 results19.4.2024 07:00:00 CEST | Press release
Issy-les-Moulineaux, April 19, 2024 Sodexo (Euronext Paris FR 0000121220-OTC: SDXAY) Sodexo announces solid H1 Fiscal 2024 results Organic Revenue growth +8.5%Underlying operating profit +16.9% at constant currencies, margin up +40 bpsFiscal 2024 guidance:Organic growth now expected at the top of the +6% to +8% rangeUnderlying operating profit margin improvement confirmed at +30 to +40 bps, at constant currencies At the Board of Directors meeting held on April 18, 2024, chaired by Sophie Bellon, the Board closed the Consolidated accounts for the First half Fiscal 2024 ended February 29, 2024. First half Fiscal 2024 key figures (in million euros)H1 FISCAL 2024H1 FISCAL 2023 RESTATEDDIFFERENCEDIFFERENCE CONSTANT RATESRevenues12,10111,581 +4.5% +7.8%Organic revenue growth +8.5% +12.9%UNDERLYING OPERATING PROFIT612545+12.3%+16.9%UNDERLYING OPERATING PROFIT MARGIN5.1%4.7%+40bps+40bpsOther operating income & expenses30(36)OPERATING PROFIT642509+26.1%+30.1%Net financial expense(46)(43)Tax cha
Pluxee delivers strong performance in the First Half and raises Fiscal 2024 Organic revenue growth and Recurring EBITDA margin objectives19.4.2024 07:00:00 CEST | Press release
First Half Fiscal 2024 Results Issy-les-Moulineaux, France – April 19, 2024 First Half Fiscal 2024 highlights Successful spin-off and listing on Euronext Paris on February 1, 2024 Organic revenue growth of +24% incl. +26% in Q2, reflecting buoyant performance across all regions Strong Recurring EBITDA at €201 million, i.e. +28% organic growth; 34.4% margin at constant rates Net profit of €68 million reflecting higher one-time items, mostly spin-off related Recurring free cash flow of €228 million, with strong Recurring Cash conversion of 113%Net cash position of €1,065 million, increasing by €206 million since August 31, 2023Fiscal 2024 financial objectives raised: Organic revenue growth expected between 15% to 17% and Recurring EBITDA margin expected at 35% at least including standalone costs at constant rates, while reaffirming all mid-term targets First Half Fiscal 2024 key figures (in millions of euros)H1 FY 2024H1 FY 2023Variation (%)Variation at constant rate (%)Total revenues593
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer19.4.2024 07:00:00 CEST | Press release
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selection Basel, 19 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours ≥ 4 cm or node positive), as detected by an FDA-approved test. Alecensa is now the first and on
Evs Invites Its Shareholders to the Ordinary General Meeting and an Extraordinary General Meeting on May 21, 202419.4.2024 06:30:00 CEST | Press release
Publication on April 19, 2024, at 6:30 am before market opening Regulated information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS INVITES ITS SHAREHOLDERS TO THE ORDINARY GENERAL MEETING AND AN EXTRAORDINARY GENERAL MEETING ON MAY 21, 2024 EVS Broadcast Equipment, leading provider of live video production systems, published today the invitation to its Ordinary General Meeting, to be held on May 21, 2024, at 11 am, at its registered office in Liège, to deliberate on the agenda available on the website of the company (see link below). Aside from the usual topics, including the 2023 annual and sustainability reports, the Board of Directors will propose to the Shareholders to approve the following resolutions: The payment of a total gross dividend of EUR 1.10 per share (including the interim dividend of EUR 0.50 paid in November 2023);A profit-sharing plan in the form of a grant of 36 EVS shares for each EVS employee, in proportion to
Icelandic Salmon - Annual Report for 202319.4.2024 06:00:00 CEST | Press release
Bíldudalur, 19 April 2023 Icelandic Salmon AS (Euronext Growth Oslo and First North Iceland: ISLAX) has today published its integrated Annual Report for 2023, including sustainability reporting and complete annual accounts with notes. The report is attached and available on the company‘s website: https://arnarlax.is/investors/ “In 2023, Icelandic Salmon supplied the world markets with a record-breaking 17,919 tonnes of salmon, thanks to the dedicated work of our employees. Despite facing many challenges this year - including macroeconomic changes, geopolitical tensions, and biological obstacles – we prioritised the health and wellbeing of our fish. Looking ahead, we are committed to sustaining this priority while growing our operations," Bjørn Hembre, CEO of Icelandic Salmon and Arnarlax says. In Bjørn‘s letter, which in included in the report, he writes: “Salmon farming holds great promise for Iceland, in terms of future jobs and economic growth. During the past few years, we have see